Murphy Polly A.'s Form 4 filing
Atea Pharmaceuticals, Inc. (AVIR) · filed May 20, 2026
- Accession no.
- 0001193125-26-232612
- Filed
- May 20, 2026
- Trade date
- May 18, 2025
- Filing delay
- 367 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $25.4K. It was filed 367 days after the trade, past the 2-business-day deadline.
This filing was later replaced by the amendment 0001193125-26-235039 (May 21, 2026). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Murphy Polly A.CIK 0001829248 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 18, 2025 | Common Stock | PPurchaseAcquired | +6,100 | $4.17F1 | +$25,437 | 92,145 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $4.14 to $4.19 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.